MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix: Reports, Publications & Metrics
Triple Helix: Regional Innovation Clusters (RIC)s
Intermediaries: Triple Helix Regional Innovation Clusters (RIC)s
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Industry: Research Triangle, North Carolina
*Bioscience Regional Clusters & HotSpots
*Industry: Northern California & Silicon Valley
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL)*
Organization & Developments: Rigel
Parents
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL)*
Children
2018: Reader Inquiry: Is Rigel Pharmaceuticals Due For A Near Term Breakout? - Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)
2018: Rigel Fumbles A Phase 2, Can Stage A Potential Comeback With FDA Approval_seekingalpha.com
2018: Rigel Pharmaceuticals Is In Bargain Territory - Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)
2019: A Look At Rigel's Partnered Pipeline - Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)
2019: Rigel Makes Progress, But Doesn't Make A Big Deal About It_seekingalpha.com
2019: Rigel Pharmaceuticals: Still Underfollowed And Trading At A Discount_seekingalpha.com
2019: Rigel's Q2 Earnings Beat Provides Confidence In Commercial Strategy_seekingalpha.com
2020: Rigel Pharmaceuticals: An Interesting Asset At Reasonable Price
2020: Rigel: Fostamatinib Joins The COVID-19 Campaign And Resuscitates My Bullish Outlook
2021: Rigel Pharma: Positive Data Supports Use Of Tavalisse In COVID-19 As Variants Subterfuge Vaccines
2021: Rigel Pharmaceuticals: Escalating Value Drivers Improve Upside Potential
2022: Rigel Pharmaceuticals Provides An Opportunity For Investors Or An Acquirer_ seekingalpha.com
2022: Rigel Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2023: MD Anderson and Rigel collaborate to advance olutasidenib in AML and other cancers
2023: Rigel Pharmaceuticals Q1 Preview: A 2-Drug Company Pushing For Profitability_seekingalpha.com
2023: Rigel Pharmaceuticals: Push To Profitability Continues, But COVID Beacon Seems Extinguished_ seekingalpha.com
2024: Blueprint’s Cancer Drug Gavreto Finds New Home at Rigel after Roche Split
2024: Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships
2024: Rigel Pharmaceuticals Provides Business Update
2024: Rigel Pharmaceuticals: Gavreto Deal Expands Growth Prospects_ seekingalpha.com
2024: Rigel Pharmaceuticals: Looking For More Growth_seekingalpha.com
2024: Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy_seekingalpha
2024: Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents_ seekingalpha.com
2024: Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential
2024: Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report
2024: Rigel Pharmaceuticals' SWOT analysis: stock shows promise amid challenges
2025: 3 Biopharma Names I Am Buying After Avadel's Buyout | Seeking Alpha
2025: Rigel Looks Interesting, But Let's Wait For A Lower Price
2025: Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum
2025: Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2026: Lilly reneges on remainder of Rigel deal in another blow for RIPK1 inhibitors
Jumps
*Key People: Rigel
Finance & Acquisitions: Rigel